Drug intelligence / Profile preview

SYS6033

Development stage: Unknown
Lead developer: CSPC Megalith Biopharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

SYS6033 is a humanized monoclonal antibody targeting interleukin-33 (IL-33), developed by CSPC Megalith Biopharmaceutical. IL-33 is an alarmin cytokine released from damaged epithelial cells that plays a critical role in initiating and driving Type 2 inflammation. By binding to IL-33, SYS6033 prevents its interaction with the ST2 receptor, thereby suppressing the activation of Th2 cells, ILC2s, and other immune cells involved in the pathogenesis of allergic and inflammatory diseases. It is primarily being investigated for the treatment of atopic dermatitis and other inflammatory conditions like asthma.

Targets

IL4R (Interleukin-4 receptor alpha subunit)

Beyond the preview

Go deeper on SYS6033.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYS6033.

Explore the full profile